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ABSTRACT
Objective: Patient-reported outcomes (PROs) are measures
of patients’ health status provided directly by patients and
when utilized in clinical trials, multiple language versions
may be needed. The overactive bladder questionnaire (OAB-
q), a self-administered PRO assessing symptom bother and
health-related quality of life (HRQL) in patients with OAB,
was developed in US English and has been translated into
more than 40 languages. This analysis evaluated the psycho-
metric equivalence of ﬁve language versions of the OAB-q.
Methods: The Disease Management Study (DMS) was a
multicenter, double-blind, placebo-controlled, parallel group,
randomized study in adults with OAB. Participants com-
pleted the OAB-q, 3-day micturition diaries, and the patient’s
perception of bladder condition (PPBC) at baseline and
weeks 1 and 12 of treatment.
Results: Data from 398 patients from ﬁve countries were
analyzed: Denmark (N = 71), Germany (N = 127), Poland
(N = 60), Sweden (N = 94), and Turkey (N = 46). Partici-
pants were a mean of 57.4 years old; 31% were male; and
almost all were Caucasian. Cronbach alphas for the OAB-q
symptom bother subscale = 0.71 to 0.83 and 0.82 to 0.94
for the HRQL subscales (concern, coping, sleep, and social)
across all ﬁve languages. OAB-q subscales were signiﬁcantly
correlated with PPBC in all languages. Mean baseline to week
12 change scores = -21.4 to -30.3 for symptom bother and
5.2 to 36.0 for the HRQL subscales. Effect sizes for the
symptom bother subscale = 0.92 to 2.79 and 0.21 to 1.30 for
the HRQL subscales.
Conclusion: OAB-q language versions of Danish, German,
Polish, Swedish, and Turkish demonstrated acceptable psy-
chometric characteristics, including internal consistency reli-
ability, construct validity, and responsiveness.
Keywords: overactive bladder, patient-reported outcomes,
questionnaire, translations.
Introduction
Patient-reported outcomes (PROs) are measures of a
patient’s health status provided directly from the
patient [1]. PROs can be used to assess such outcomes
as health-related quality of life (HRQL), symptoms,
patient satisfaction, and social, emotional and physical
functioning. As with any clinical assessment, the
assessment of PROs relies on the use of questionnaires
with demonstrated validity and reliability [1–4].
PROs utilized in multinational clinical trials may
require multiple language versions of a questionnaire.
Standard methodology for linguistic validation of
questionnaires includes forward translation into the
target language by two native language speakers, with
comparison and reconciliation of the translations, and
then at least one backward translation to the initial
language, with comparison of the translations to the
primary questionnaire. The translated versions are
reviewed by lay persons and experts, and revisions are
made if necessary. The ﬁnal version is then tested with
patients in the target language [5–8]. With the linguis-
tic validation, conceptual equivalence is often also
assessed in the various language versions of a question-
naire [9,10]. Thus, after completing this process, the
questionnaire is considered to be linguistically and
conceptually equivalent.
The next step in successful questionnaire translation
is performing a psychometric evaluation of each new
language version and determining the psychometric
equivalence of the different language versions [1].
Psychometric evaluation includes examination of the
instrument’s validity and reliability, and occurs
throughout the use of the questionnaire in the target
patient population. The evaluation of psychometric
equivalence involves the assessment of the psychomet-
ric properties of each language version of a question-
naire when utilized within the same target patient
population [11–14]. Psychometric equivalence is the
extent to which the psychometric properties of the
different language versions of the questionnaire are
similar, though not necessarily the same [9]. The deter-
mination of psychometric equivalence is paramount to
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determining if data from the different language versions
can be combined for analyses in multinational clinical
trials [7].
The overactive bladder questionnaire (OAB-q) is a
33-item, self-administered, disease-speciﬁc question-
naire to assess symptom bother and HRQL in patients
with OAB [15]. The OAB-q was originally developed
in English for the United States and has been translated
and culturally validated into numerous languages
using accepted translation methodology [5]. Although
this translation methodology is designed to produce a
culturally valid questionnaire, it does not ensure the
psychometric validity of the translated versions. This
post hoc analysis was performed to evaluate the psy-




The Disease Management Study (DMS) was a multi-
center, double-blind, placebo-controlled, parallel
group, randomized study of adults with OAB. Patients
were eligible for DMS if they were 18 years of age
and reported OAB symptoms for 3 months before
the screening visit, urinary frequency of 8 micturi-
tion episodes per 24 hours, and at least three episodes
in 3 days of urgency or urgency incontinence. Eligible
patients must also have rated the most bothersome
OAB symptom as at least moderately bothersome on
the OAB bother rating scale (BRS). Participants were
randomized (2:1) to receive either tolterodine or
placebo for 12 weeks. Four study visits occurred:
screening, baseline, week 1, and week 12. Participants
were instructed to take one capsule of study drug in the
evening before going to bed for 12 weeks. No dose
adjustment was allowed. The following questionnaires
were completed:
• OAB-q: The self-administered OAB-q measures
symptom bother (8 items) and HRQL (25 items)
with the HRQL scale consisting of four subscales:
coping, concern, sleep, and social interaction [15].
Scores range from 0 to 100; higher symptom
bother scores indicate greater reports of symptom
severity while higher HRQL scores indicate better
HRQL. The OAB-q was developed in English
based on patient input (i.e., focus groups and cog-
nitive debrieﬁng interviews), and has been vali-
dated in more than 5000 patients with continent
and incontinent OAB, in both clinical and com-
munity samples. The OAB-q has consistently dem-
onstrated good internal consistency and test-retest
reliability, concurrent and discriminant validity,
and responsiveness. The OAB-q was completed
at baseline, week 1, and week 12 in 11 languages:
Canadian English, Canadian French, Danish,
German, Italian, Dutch, Norwegian, Polish,
Spanish, Swedish, and Turkish.
• Patient’s perception of bladder condition (PPBC):
The PPBC is a validated, one-item, self-
administered questionnaire that asks the patient to
describe the perception of his/her bladder condi-
tion [16]. Patients are asked to choose the state-
ment which best describes his/her current bladder
condition, with responses ranging from 1 (“does
not cause me any problems at all”) to 6 (“causes
me many severe problems”). The PPBC was com-
pleted in 11 languages at the baseline, week 1, and
week 12 visits.
• Micturition diary: The number of daytime and
nighttime urinations, urgency episodes, and urge
incontinent episodes was collected in the micturi-
tion diary. Micturition diaries were completed in
11 languages for 3 days before the baseline, week
1, and week 12 visits.
Statistical Analyses and Analysis Sets
All patients in the safety population (i.e., all enrolled
participants, regardless of treatment assignment) were
used in the baseline-only analyses. Analyses were only
conducted on language versions of the OAB-q for
which data from at least 40 patients were available.
Responsiveness and effect size analyses were con-
ducted on the completers analysis set among patients
who had data at both baseline and week 12. No
missing subscale PRO data were imputed for the
responsiveness and analyses. As the purpose of this
analysis was to examine the psychometric properties of
the OAB-q within each language, treatment assign-
ment was not included or considered in our analyses.
SAS statistical software Version 9.1.3 (SAS Insti-
tute, Cary, NC) was used for all analyses. All statistical
tests were two-tailed and were conducted with type I
error probability ﬁxed at 0.05. Summaries of categori-
cal variables included the frequency and the percentage
of patients within each category. Comparisons of cat-
egorical data were performed using chi-square tests
(and Fisher’s exact test for cases when the frequency
per cell was less than 5). Continuous variables were
summarized with the following measures of location
and dispersion: mean, median, SD, minimum, and
maximum.
To assess internal consistency reliability, Cronbach
alphas were calculated for each OAB-q subscale score
by country at baseline, week 1, and week 12. Coefﬁ-
cients were compared qualitatively across language
versions. The mean baseline scores for each OAB-q
subscale were examined by language version using
general linear models (PROC GLM) to control for
selected demographic and clinical characteristics (e.g.,
age, sex, years since OAB diagnosis, and bladder diary
variables); adjustments were made using Scheffe’s
method of multiple comparisons. The relationship of
OAB-q Language Psychometric Equivalence 1097
the OAB-q subscales with other measures (e.g., BRS
scores, micturition diary variables) was examined at
each baseline, week 1 and week 12 by language version
using Spearman’s correlations.
Responsiveness is an important component of con-
struct validity of a PROmeasure and is critical for PRO
end points used in clinical trials [2–4,17]. The respon-
siveness of the OAB-q was examined by language
version with change in the OAB-q subscales calculated
by: week 12 visit score—baseline visit score. Pairwise
comparisons between differences in least squares means
from aGLMmodel with age, sex, years since diagnosis,
and baseline score as covariates by language were per-
formed using Scheffe’s test adjusting for multiple com-
parisons. Effect sizes were also calculated by language
version. Effect size was calculated by taking the differ-
ence inmean score from baseline toweek 12, divided by
the SD of baseline scores for all subjects (mean score
at baseline—mean score at week 12  SD of baseline
scores). Effect size is characterized as small (0.20),
moderate (0.50), or large (0.80) following the guide-
lines proposed by Cohen [18]. Responsiveness and
effect size calculations utilized the completers analysis
set among patients who had data at both baseline and
week 12, regardless of treatment assignment.
Results
Six hundred seventeen participants were enrolled from
66 centers in 11 countries; however, only ﬁve countries
enrolled 40 or more patients. As such, data from 398
patients were analyzed from the following countries:
Denmark (N = 71), Germany (N = 127), Poland
(N = 60), Sweden (N = 94), and Turkey (N = 46).
Demographic characteristics for each country are
summarized in Table 1. Participants were a mean of
57.4 years of age and 31% were male. Of the 398
patients, 397 were Caucasian. Participants had
received a diagnosis of OAB a mean of 5.0 years before
enrollment in this study.
Baseline Score Comparability
The mean OAB-q baseline scores were compared by
country (Table 2). To control for OAB severity and
other variations, the following covariates were used in
the GLM model: age, sex, years since diagnosis, fre-
quency of daytime urinations, nocturia episodes,
urgency episodes, and incontinence episodes. Baseline
symptom bother scores ranged from 63.5 (Swedish) to
73.0 (Polish), indicating moderate to high symptom
bother. Baseline HRQL subscale scores ranged from
31.5 (concern: Turkish) to 81.6 (social interaction:
Danish), indicating low to high HRQL impact. Social
activities were impacted the least overall (51.6
[Turkish] to 81.6 [Danish]), while coping demon-
strated the greatest impact (37.9 [Turkish] to 54.8
[Danish]). There were signiﬁcant differences among
some of the language versions for the symptom bother
subscale and also for each of the HRQL subscales with
the Danes consistently reporting highest HRQL and
lowest symptom bother.
Internal Consistency Reliability
Cronbach’s alphas were calculated for each OAB-q
subscale score for each visit for each of the ﬁve coun-
tries (Table 3 presents baseline data). The OAB-q
symptom bother subscale and HRQL subscales
(concern, coping, sleep, and social interaction) demon-
Table 1 Baseline demographic and clinical characteristics
Characteristic
Language analysis











Age (mean, SD) 57.4 (13.4) 58.5 (14.0) 57.9 (12.9) 59.5 (12.4) 58.3 (12.4) 49.7 (14.7)
Sex (% male) 30.7 47.9 18.9 16.7 44.7 26.1
Race (N,%)
Caucasian 397 (99.8) 70 (98.6) 127 (100) 60 (100) 94 (100) 46 (100)










Premenopausal 89 (32.3) 11 (29.4) 33 (32.0) 12 (24.0) 19 (36.5) 14 (41.2)
Postmenopausal 187 (67.8) 26 (70.3) 70 (68.0) 38 (76.0) 33 (63.5) 20 (58.8)
Smoking status (N,%)
Current smoker 81 (20.4) 27 (38.0) 15 (11.8) 11 (18.3) 15 (16.0) 13 (28.3)
Ex-smoker 104 (26.1) 13 (18.3) 37 (29.1) 14 (23.3) 34 (36.2) 6 (13.0)
Nonsmoker 213 (53.5) 31 (43.7) 75 (59.1) 35 (58.3) 45 (47.9) 27 (58.7)
Years since OAB diagnosis
(mean, SD)
5.03 (6.52) 8.04 (7.47) 4.34 (6.36) 5.19 (5.02) 6.03 (6.91) 0.06 (0.10)
OAB, overactive bladder.
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strated good internal consistency reliability across all
ﬁve languages. Symptom bother Cronbach alphas
ranged from 0.71 (Polish) to 0.83 (Turkish); Cronbach
alphas for the HRQL subscales ranged from 0.82
(social interaction: Danish) to 0.94 (coping: Swedish).
Cronbach’s alphas for each of the subscales in each of
the languages exceeded the generally accepted value of
0.70 for aggregate data. Cronbach’s alphas for each
of the subscales in each of the languages at weeks 1
and 12 were consistent with baseline and also
exceeded 0.70 (data on ﬁle).
Correlations
Symptom bother scores at baseline were signiﬁcantly
correlated with the PPBC in all languages (r = 0.49–
0.56; P < 0.001) and also with daytime urgency epi-
sodes in Danish, German, and Swedish (r = 0.23–0.36;
P < 0.05). The HRQL sleep subscale was signiﬁcantly
correlated with nocturnal micturitions (r = 0.28–0.71;
P < 0.001) in all languages except Turkish and noctur-
nal urgency episodes (r = 0.40–0.63; P < 0.005) in all
languages except Turkish and German. All HRQL
subscales were signiﬁcantly correlated with PPBC in
all languages except Danish (r = 0.29–0.69; P < 0.01).
The correlations at week 12 increased for all subscales
and were similar but of greater magnitude than the
baseline correlations. These correlations were ex-
pected, given that both instruments assess aspects of
the patient’s perception of the impact of OAB.
Correlations among the HRQL subscales and the
micturition diary variables were small, with the excep-
tion of the coping subscale in Polish with nighttime
urinations and the sleep subscale in Danish, Polish, and
Swedish with both nighttime urinations and nighttime
urge episodes. Given that the OAB-q and micturition
diaries measure two different aspects of OAB, these
correlations were in the expected range. These results
demonstrate good construct validity of the OAB-q
in these languages. The pattern and magnitude of
these correlations are consistent with previous research
[15].
Responsiveness and Effect Size
The OAB-q was highly responsive across all languages
(Table 4). Mean change from baseline to week 12 for
symptom bother ranged from -21.4 (Danish) to -30.3
(Polish). HRQL subscale mean changes ranged from
5.2 (social interaction: Danish) to 36.0 (concern:
Turkish). Signiﬁcant differences (P < 0.0001) were
present in change scores among the language versions
with Poland and Turkey consistently reporting the
greatest change.
Effect sizes were also calculated by language version
(Table 5). Effect sizes were large for the symptom
bother subscale across language versions, ranging from
1.02 (Danish) to 2.79 (Polish). HRQL subscale effect
sizes ranged from 0.25 (sleep: Danish) to 1.66
(concern: Turkish).















Symptom bother† 63.7 (1.8) 64.9 (1.4) 73.0 (1.9) 63.5 (1.5) 71.9 (2.4) 14.9*** 2*,5*,8**
Coping‡ 54.8 (2.8) 45.8 (2.1) 39.7 (3.0) 50.7 (2.3) 37.9 (3.7) 11.3*** 2**,4*
Concern‡ 58.4 (2.5) 49.2 (2.0) 42.1 (2.7) 55.7 (2.1) 31.5 (3.4) 15.0*** 2***,4***,7***,8**,10***
Sleep‡ 58.5 (2.7) 54.5 (2.1) 45.5 (3.0) 54.2 (2.3) 45.9 (3.7) 17.5*** 2*
Social‡ 81.6 (2.6) 73.8 (2.0) 59.9 (2.8) 73.2 (2.2) 51.6 (3.5) 19.0*** 2***,4***,5**, 7***,8**,10***
HRQL total‡ 62.4 (2.2) 54.1 (1.7) 45.7 (2.4) 57.3 (1.8) 40.4 (3.0) 20.2*** 2***,4***,7**,8**,10***
P-values: Pairwise comparisons between differences in least squares (LS) means from GLM model with age, sex, years since diagnosis, frequency of daytime urinations, nocturia
episodes, urgency episodes, and incontinence episodes as covariates by language were performed using Scheffe’s test adjusting for multiple comparisons. Comparisons not
signiﬁcant unless noted: 1 =Danish vs. German; 2 =Danish vs. Polish; 3 =Danish vs. Swedish; 4 =Danish vs.Turkish; 5 =German vs. Polish; 6 =German vs. Swedish; 7 =German vs.
Turkish; 8 = Polish vs. Swedish; 9 = Polish vs.Turkish; and 10 = Swedish vs.Turkish. P-values are: *<0.05., **<0.01, ***<0.001.
†Scores range from 0 to 100; higher scores indicate greater symptom bother.
‡Scores range from 0 to 100; higher scores indicate better health-related quality of life (HRQL).
Table 3 Internal consistency reliability of OAB-q at baseline (N = 398)
OAB-q subscale
Cronbach’s alpha
Danish German Polish Swedish Turkish
Symptom bother 0.81 0.75 0.71 0.81 0.83
Coping 0.92 0.91 0.91 0.94 0.87
Concern 0.90 0.87 0.91 0.90 0.85
Sleep 0.89 0.91 0.92 0.93 0.93
Social 0.82 0.91 0.88 0.87 0.88
HRQL total 0.94 0.95 0.96 0.96 0.96
HRQL, health-related quality of life; OAB-q, overactive bladder questionnaire.
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Discussion
This evaluation of the psychometric equivalence of ﬁve
language versions of the OAB-q found them all to
demonstrate adequate psychometric properties. Base-
line scores across all language versions were compa-
rable to scores from other studies of patients with OAB
[19], and overall worse than normal controls [20].
Interestingly, Danes reported the lowest symptom
bother and highest HRQL on all subscales, while
Turks and Poles reported high symptom bother and the
lowest HRQL.
OAB-q score changes from baseline to 12 weeks
were also consistent with other studies of patients who
undergo treatment for OAB [21]. Effect sizes in this
study were generally consistent with those found in
previous studies [19,21].
Although there were statistically signiﬁcant differ-
ences among the baseline scores of various countries,
the scores were still within acceptable ranges. The
differences in scores could be due to cultural variations
in reporting of symptoms, and attitudes toward OAB
and urinary issues. Questionnaires are usually initially
developed and validated in a single language. When
multiple language versions are needed, that primary
questionnaire is translated word-for-word or phrase-
for-phrase into the target languages. Although the
translations may be technically correct, the topic may
not be appropriate or applicable in the target culture.
In addition, cultural customs and norms are
entrenched in patients’ responses to questionnaires.
Some cultures value stoicism while others are more
open. These cultural beliefs can affect patients’
responses to their medical conditions and also their
questionnaire responses. Although a questionnaire
may have undergone full translation and be psycho-
metrically valid, mean scores for one country could be
vastly different than mean scores for another country
because of these cultural variations. A questionnaire
on a topic as sensitive as OAB and urinary inconti-
nence could potentially be greatly affected by these
cultural variations. This effect is demonstrated in the
signiﬁcant differences in 6 of the 10 comparisons
between the language versions on the social subscale.
Coping—which one would not expect to be as affected
by cultural norms as social functioning—had more
comparable scores at baseline. Given these issues, all
scores are within acceptable ranges, indicating good
psychometric properties and equivalence.
The authors acknowledge the limitations of these
analyses, including the extreme variations in sample
sizes across the countries. The patients in Turkey had
recently received a diagnosis of OAB before enrollment
in the study (0.06 years); patients in the other coun-
Table 4 Baseline to week 12 overactive bladder questionnaire (OAB-q) mean change scores
OAB-q subscale














Symptom bother† -21.4 (2.0) -24.2 (1.6) -30.3 (2.1) -20.1 (1.8) -29.8 (2.8) 42.5*** 2*,8**
Coping‡ 13.3 (2.9) 22.1 (2.3) 24.7 (3.0) 15.5 (2.6) 29.3 (4.0) 15.6*** 4*
Concern‡ 15.0 (2.8) 21.7 (2.2) 26.4 (2.9) 14.5 (2.6) 36.0 (3.9) 21.1*** 4**,7*,10***
Sleep‡ 9.1 (2.9) 15.0 (2.3) 21.3 (3.0) 12.7 (2.7) 25.5 (4.1) 15.7*** 4*
Social‡ 5.2 (2.8) 8.6 (2.2) 20.4 (2.9) 9.4 (2.6) 28.8 (3.9) 9.6*** 2**,4***,5*,7***,10**
HRQL total‡ 11.0 (2.4) 17.7 (1.9) 24.2 (2.5) 13.7 (2.2) 30.3 (3.4) 20.4*** 2**,4***,7*,8*,10**
P-values: Pairwise comparisons between differences in least squares (LS) means fromANCOVA model with age, sex, years since diagnosis, baseline score, and frequency of daytime
urinations, nocturia episodes, urgency episodes, and incontinence episodes as covariates by language were performed using Scheffe’s test adjusting for multiple comparisons.
Comparisons not signiﬁcant unless noted: 1 =Danish vs.German; 2 =Danish vs. Polish; 3 =Danish vs. Swedish; 4 =Danish vs.Turkish; 5 =German vs. Polish; 6 =German vs. Swedish;
7 =German vs.Turkish; 8 = Polish vs. Swedish; 9 = Polish vs.Turkish; and 10 = Swedish vs.Turkish. P-values are: *<0.05, **<0.01, ***<0.001.
†Scores range from 0 to 100; higher scores indicate greater symptom bother.
‡Scores range from 0 to 100; higher scores indicate better health-related quality of life (HRQL).













Symptom bother* -1.02 -1.98 -2.79 -1.07 -2.11
Coping† 0.58 1.14 1.36 0.59 1.30
Concern† 0.70 1.29 1.33 0.59 1.66
Sleep† 0.25 0.76 1.03 0.36 1.22
Social† 0.30 0.55 0.86 0.35 0.95
HRQL total† 0.64 1.17 1.31 0.57 1.45
*Scores range from 0 to 100; higher scores indicate greater symptom bother.
†Scores range from 0 to 100; higher scores indicate better health-related quality of life.
HRQL, health-related quality of life; OAB-q, overactive bladder questionnaire.
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tries had received diagnosis a mean of 4 to 8 years
before enrollment. While the models comparing mean
scores utilized years since OAB diagnosis as a covariate
to adjust for this difference, this could possibly have
an effect on the comparisons. Also, the Turkish langu-
age analyses utilized a relatively small sample of 46
patients, possibly affecting the comparisons across
language versions. Country was used as a proxy for
language version, because we presumed that only one
questionnaire translation was utilized for each country.
Although the OAB-q was completed in 11 languages,
only ﬁve of the languages were included in this psy-
chometric equivalence study because of the small
sample sizes in the remaining languages. Further evalu-
ation of the remaining language versions is warranted.
Conclusions
The OAB-q language versions of Danish, German,
Polish, Swedish, and Turkish demonstrated acceptable
internal consistency reliability, good construct validity,
and small to large effect sizes across language versions.
Results indicate that the OAB-q is psychometrically
valid in Danish, German, Polish, Swedish, and
Turkish.
Source of ﬁnancial support: Funding for this article was
provided by Pﬁzer.
References
1 US Department of Health and Human Services. 2006.
Guidance for industry patient-reported outcome mea-
sures: use in medical product development to support
labeling claims. Available from: http://www.fda.gov/
cder/guidance/5460dft.pdf [Accessed February 2,
2006].
2 Leidy NK, Revicki DA, Geneste B. Recommendations
for evaluating the validity of quality of life claims for
labeling and promotion. ValueHealth 1999;2:113–27.
3 Revicki DA, Osoba D, Fairclough D, et al. Recom-
mendations on health-related quality of life research
to support labeling and promotional claims in the
United States. Qual Life Res 2000;9:887–900.
4 Hays RD, Revicki DA. Reliability and validity
(including responsiveness). In: Fayers P, Hays RD,
eds. Assessing Quality of Life in Clinical Trials:
Methods and Practice (2nd edn). Oxford: Oxford
University Press, 2005.
5 Acquadro C, Kopp Z, Coyne KS, et al. Translating
overactive bladder questionnaires in 14 languages.
Urology 2006;67:536–40.
6 Guillemin F, Bombardier C, Beaton D. Cross-cultural
adaptation of health-related quality of life measures:
literature review and proposed guidelines. J Clin Epi-
demiol 1993;46:1417–32.
7 Mear I. Difﬁculties of international clinical trials: cul-
tural adaptation of quality of life questionnaires. In:
Chassany O, Caulin C, eds. Health-Related Quality
of Life and Patient-Reported Outcomes: Scientiﬁc
and Useful Outcome Criteria. Paris: Springer Verlag
Publishers, 2002.
8 Scientiﬁc Advisory Committee of the Medical Out-
comes Trust. Assessing health status and quality-of-
life instruments: attributes and review criteria. Qual
Life Res 2002;11:193–205.
9 Herdman M, Fox-Rushby J, Badia X. A model of
equivalence in the cultural adaptation of HRQoL
instruments: the universalist approach. Qual Life Res
1998;7:323–35.
10 Acquadro C, Jambon B, Ellis D, Marquis P. Language
and translation issues. In: Spilker B, ed. Quality of
Life and Pharmacoeconomics in Clinical Trials (2nd
edn). Philadelphia, PA: Lippincott-Raven, 1996.
11 Devins GM, Beiser M, Dion R, et al. Cross-cultural
measurements of psychological well-being: the psy-
chometric equivalence of Cantonese, Vietnamese, and
Laotian translations of the affect balance scale. Am J
Public Health 1997;87:794–9.
12 Hurtado MP, Angeles J, Blahut SA, Hays RD. Assess-
ment of the equivalence of the Spanish and English
versions of the CAHPS Hospital Survey on the quality
of inpatient care. Health Serv Res 2005;40(6 Part
2):2140–61.
13 Kleijn WC, Ogoshi K, Yamaoka K, et al. Conceptual
equivalence and health-related quality of life: an
exploratory study in Japanese and Dutch cancer
patients. Qual Life Res 2006;15:1091–101.
14 Martin M, Blaisdell B, Kwong JW, Bjorner JB. The
Short-Form Headache Impact Test (HIT-6) was psy-
chometrically equivalent in nine languages. J Clin
Epidemiol 2004;57:1271–8.
15 Coyne K, Revicki D, Hunt T, et al. Psychometric vali-
dation of an overactive bladder symptom and health-
related quality of life questionnaire: the OAB-q. Qual
Life Res 2002;11:563–74.
16 Coyne KS, Matza LS, Kopp Z, Abrams P. The vali-
dation of the patient perception of bladder condition
(PPBC): a single-item global measure for patients with
overactive bladder. Eur Urol 2006;49:1079–86.
17 Revicki DA, Cella D, Hays RD, et al. Responsiveness
and minimal important differences for patient
reported outcomes. Health Qual Life Outcomes
2006;4:70.
18 Cohen J. Statistical Power Analysis for the Behavioral
Sciences (2nd edn). Hillsdale, NJ: Lawrence Erlbaum
Associates, 1988.
19 Coyne KS, Matza LS, Thompson CL. The responsive-
ness of the Overactive Bladder Questionnaire (OAB-
q). Qual Life Res 2005;14:849–55.
20 Coyne KS, Payne C, Bhattacharyya SK, et al. The
impact of urinary urgency and frequency on health-
related quality of life in overactive bladder: results
from a national community survey. Value Health
2004;7:455–63.
21 Coyne KS, Matza LS, Thompson CL, et al. Determin-
ing the importance of change in the overactive bladder
questionnaire. J Urol 2006;176:627–32; discussion
632.
OAB-q Language Psychometric Equivalence 1101
